5 Results for "

Endochondral bone formation

" in MedChemExpress (MCE) Product Catalog:
Products (5)

5 Results for "Endochondral bone formation" in MCE Product Catalog:

Cat. No.: HY-159642
CAS No.: 2800223-30-5
Synonyms: TYRA-300
Target:  

FGFR ERK

Research Areas:  

Metabolic Disease Cancer

Dabogratinib (TYRA-300) is an orally active, selective FGFR3 inhibitor with an IC50 of 11 nM. Dabogratinib exhibits antitumor activity against urothelial carcinoma and solid tumors. Dabogratinib downregulates the FGFR3 and ERK1/2 signaling pathways, and induces tumor growth inhibition and regression in FGFR3-altered xenograft models. Dabogratinib promotes chondrocyte proliferation and differentiation, drives endochondral bone formation and overall body growth, partially restores long bone proportions, and improves craniofacial and spinal morphology. Dabogratinib can be used for the research of metastatic urothelial carcinoma, achondroplasia and hypochondroplasia .
loading...
    loading...
Cat. No.: HY-108624
CAS No.: 1421365-63-0
Purity:  98.83%
CYM 50769 is a non-peptidic selective antagonist of neuropeptides B and W receptor 1 (NPBWR1). CYM 50769 can attenuates the NPW-23-induced cell proliferation in ATDC5. CYM 50769 can be used for researching endochondral bone formation .
loading...
    loading...
Cat. No.: HY-159642G
CAS No.: 2800223-30-5
Synonyms: TYRA-300 (GMP)
Dabogratinib (TYRA-300) (GMP) is Dabogratinib (HY-159642) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Dabogratinib is an orally active, selective FGFR3 inhibitor with an IC50 of 11 nM. Dabogratinib exhibits antitumor activity against urothelial carcinoma and solid tumors. Dabogratinib downregulates the FGFR3 and ERK1/2 signaling pathways, and induces tumor growth inhibition and regression in FGFR3-altered xenograft models. Dabogratinib promotes chondrocyte proliferation and differentiation, drives endochondral bone formation and overall body growth, partially restores long bone proportions, and improves craniofacial and spinal morphology. Dabogratinib can be used for the research of metastatic urothelial carcinoma, achondroplasia and hypochondroplasia .
loading...
    loading...
Cat. No.: HY-108624R
CAS No.: 1421365-63-0
CYM 50769 (Standard) is the analytical standard of CYM 50769 (HY-108624). This product is intended for research and analytical applications. CYM 50769 is a non-peptidic selective antagonist of neuropeptides B and W receptor 1 (NPBWR1). CYM 50769 can attenuates the NPW-23-induced cell proliferation in ATDC5. CYM 50769 can be used for researching endochondral bone formation .
loading...
    loading...
Cat. No.: HY-174774
Target:  

mRNA

Research Areas:  

Cancer

Human BMPR1B mRNA encodes the human bone morphogenetic protein receptor type 1B (BMPR1B) protein, a family of transmembrane serine/threonine kinases. The ligands of this receptor are BMPs, which are members of the TGF-beta superfamily. BMPs are involved in endochondral bone formation and embryogenesis.
loading...
    loading...